New shot for dust mite allergies enters early human testing
NCT ID NCT04184895
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug, ASP2390, in 28 adults with house dust mite allergies. The main goal is to check safety and side effects, and also to see how the immune system responds. Participants receive multiple small doses under the skin to find the best and safest dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC TO HOUSE DUST MITES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site DE49001
Berlin, Germany
-
Site DE49002
Hanover, Germany
Conditions
Explore the condition pages connected to this study.